We are living through a boom in “biological age” tests. Spit in a tube, mail it off, get a number back telling you your body is 47 when your birthday says 53. It’s a compelling pitch. But a study published this week in Nature Aging delivers a quiet, important correction to how we should be using these tools — and it’s the most useful methodological finding I’ve seen in a while.

Researchers at the National Institute on Aging analyzed DNA methylation profiles from 699 European adults (average age ~63), applying seven different epigenetic aging clocks to samples taken at multiple time points — two readings for 376 people, three readings for 323 (nad.com summary of the Nature Aging study). The question was simple: does measuring your aging repeatedly over time predict death better than a single snapshot?

The answer was a clear yes. Faster aging captured across two or three time points robustly predicted higher mortality risk, outperforming any single measurement — with one reported hazard ratio of 1.23, meaning a 23% higher death rate than average. In other words, the slope matters more than the dot. A single biological-age reading is a photograph; what actually forecasts your health is the movie — the direction and pace your aging is moving.

Why does this matter beyond statistics? Because it reframes what these tests are for. A one-time number is easy to over-interpret and easy to sell. But the real value — and the only rigorous way to know whether a diet, an exercise program, or a drug is actually bending your aging curve — is to measure the same person over time and watch the trajectory. This is the difference between a novelty and a tool.

The honest caveats. This is 699 people, all of European ancestry, in an observational dataset — the paper doesn’t fully specify the time span between readings, and the authors are upfront that we still don’t know exactly what cellular changes these methylation shifts reflect. Epigenetic clocks remain proxies, not ground truth. But the takeaway is durable and practical: if you’re going to spend money on a biological-age test, don’t buy one. Buy the baseline, change something real, and buy the follow-up. The trend is the signal.

5 QUICK HITS

1. A cheap metabolite tied to a younger biological age. In an observational study of 4,260 health enthusiasts published in Aging Cell, users of supplements showed significantly lower biological age than non-users — and delayed-release alpha-ketoglutarate (AKG) was the single supplement most strongly associated with a younger methylation age (nmn.com). AKG sits right at the crossroads of the Krebs cycle — pure metabolism. Big caveat: observational, not randomized, in an unusually health-conscious group, so this is a hypothesis to test, not a prescription.

2. Exercise’s metabolic magic has a messenger — and it’s dose-by-consistency. A meta-analysis of 50 randomized trials in 1,780 adults with overweight or obesity found that regular exercise significantly raises irisin, a muscle-derived signaling protein that improves glucose metabolism and helps turn white fat into metabolically active brown-like fat (NaturalNews summary). Alongside it: lower fasting glucose, better HOMA-IR, lower HbA1c and LDL, higher HDL. The authors’ key point — consistency over weeks and months, not single hard sessions, drives the benefit.

3. A membrane molecule that rewinds mitochondrial aging. In Nature Communications, researchers found that declining phosphatidylcholine is a major, reversible driver of age-related mitochondrial dysfunction — and simply feeding it (or its precursor choline) restored youthful mitochondrial structure in worms within two days, even in advanced age (ScienceDaily). A striking sex-specific note: the sharpest decline in humans clustered around menopause. Caveat: worms and human cell cultures, no human trial yet — but the mitochondrial-energy angle is squarely metabolic.

4. A cancer vaccine you swallow. In an exploratory phase 1 study, a genetically engineered Bifidobacterium — a common gut bacterium — was used as an oral delivery platform for a cancer vaccine, and it was well tolerated while generating both immune and early clinical responses (Medical Xpress oncology roundup). Using the gut microbiome itself as the delivery truck for immunotherapy is a genuinely novel idea. Very early — phase 1, small — but worth watching.

5. NMN + apigenin: an additive NAD+ play. Combining NMN with the CD38 inhibitor apigenin additively boosted NAD+, cut cellular senescence, improved mitochondrial function, and regenerated cartilage, bone, and muscle in aged mice — restoring young-like strength and speed (Aging Cell, via nmn.com). The effect was even mediated partly through beneficial gut bacteria. Firmly preclinical — this is 20-month-old mice, not people.

THE THROUGH-LINE THIS WEEK

Notice what nearly every item on this page has in common: mitochondria, methylation, and metabolism.

The lead says the way to know if you’re aging well is to track the trajectory of your epigenetic clock — which is, at root, a readout of your metabolic and cellular state over time. AKG is a Krebs-cycle metabolite. Irisin is the muscle’s metabolic messenger. Phosphatidylcholine restores the mitochondria — your cells’ power grid. The NMN-apigenin stack works through NAD+, the central currency of metabolism. Even the cancer vaccine rides in on your gut microbiome, itself a metabolic organ.

Here’s the frame I keep returning to: aging isn’t one thing happening to you — it’s the slow drift of your metabolic machinery, and that drift is more modifiable than we used to believe. This week’s message is almost operational. Stop treating a single biological-age number as a verdict. Establish your baseline, then pull the levers that actually move metabolism — consistent exercise, mitochondrial and metabolic support, muscle you build and keep — and re-measure. Watch the slope. If the trend is bending the right way, you’re doing the real work. That’s not a supplement you buy. It’s a system you tend.

GO DEEPER

If this landed, keep going. Subscribe to the newsletter at robertlufkinmd.substack.com to get the Brief in your inbox every week, and dig into the metabolic-root-cause framework on the Health Longevity Secrets podcast, where I take these threads apart with the researchers and clinicians doing the work.

Live well, longer,
Robert Lufkin, MD

This newsletter is for educational purposes only and is not medical advice. It does not replace a personal relationship with a qualified health care professional. Talk with your own physician before changing your diet, exercise, medications, or supplements — especially if you have a medical condition or take prescription drugs.

Intermittent fasting has spent years being sold as a stopwatch problem: keep the eating window short enough and the magic happens. A meta-analysis published this week in Diabetes & Metabolic Syndrome pushes back on that framing — and the correction is one of the most practical things I’ve read all year.

Researchers pooled 13 randomized controlled trials covering 859 adults and compared early time-restricted eating (eTRE) — front-loading calories into breakfast and lunch and finishing dinner early — against eating the same food later into the evening (Maeil Business Newspaper summary of the meta-analysis). Same window length in many cases. Different clock position. The early eaters came out ahead across the board: 1.84 kg more weight lost, 1.10 kg more body fat gone, 3.21 cm off the waist, plus significant reductions in visceral fat — the metabolically dangerous kind. Lean mass was largely preserved.

But the number that matters most to me isn’t on the scale. eTRE also improved fasting blood sugar, insulin resistance, blood pressure, and TNF-α, a key inflammatory marker. That’s the metabolic core — the machinery underneath nearly every chronic disease of aging — moving in the right direction simply by shifting when the food arrived.

The mechanism is your circadian biology. Insulin sensitivity peaks in the morning and daytime, when your body is primed to burn glucose. By evening, that same meal lingers longer in the blood and is more readily stored as fat (Maeil Business Newspaper). You are, quite literally, a different metabolic animal at 8 a.m. than at 8 p.m.

Now the honest caveats. This is a meta-analysis of modest trials — 859 people total, heterogeneous protocols, and the reporting here comes via a press summary rather than the full paper, so effect sizes should be read as directional. A strict “dinner by 4 p.m.” schedule is unrealistic for most people, and outright impossible for shift and night workers. The researchers themselves land in a sensible place: you don’t need an extreme window — just pull dinner an hour or two earlier and cut the late-night grazing. That’s a free intervention with no needle, no prescription, and a real metabolic payoff.

5 QUICK HITS

1. A longevity gene that dials down inflammation. In the Leiden Longevity Study, researchers scanning 212 groups of long-lived siblings found a rare variant in the CGAS gene — the sensor that triggers inflammation when it detects stray DNA — that appears to leave carriers with one active copy instead of two, tamping down inflammatory signaling while still clearing infections (ScienceDaily). It’s a beautiful illustration of “inflammaging” as a lever for healthspan. Big caveat: it showed up in just two families, effects are context-dependent (shutting the pathway down entirely could raise infection and cancer risk), and the work is still in vitro heading to animal models.

2. Eight preservatives, higher blood pressure. France’s NutriNet-Santé cohort of 112,395 people followed for ~7–8 years linked the highest intake of common food preservatives — including sodium nitrite (E250), potassium sorbate (E202), and citric acid (E330) — to a 29% greater risk of hypertension and 16% higher cardiovascular risk (European Heart Journal, via ScienceDaily). Proposed mechanism: oxidative stress and effects on the pancreas. Observational, so confounding applies — but nearly all of us are exposed, which makes even a modest signal worth taking seriously.

3. DASH beats the field for blood pressure. A large analysis reported across ~83,000 patients found the DASH eating pattern delivered superior blood pressure control compared with other dietary approaches (NewsTarget). Nothing exotic here — vegetables, fruit, whole grains, low sodium — but a useful reminder that the highest-leverage cardiometabolic drug is often the plate. Read the effect sizes cautiously given the secondary-source reporting.

4. Inject one tumor, watch others shrink. A redesigned CD40-agonist antibody (2141-V11) injected directly into a tumor produced whole-body responses in a phase 1 trial of 12 patients with metastatic cancer — six saw tumors shrink, two reached complete remission, and untreated distant tumors regressed too (the “abscopal” effect), without the severe toxicity that sank earlier CD40 drugs (Cancer Cell, via ScienceDaily). Extraordinary early signal — but it’s 12 people, phase 1. This is a lead to watch, not a conclusion.

5. Mediterranean diet, 21% less heart disease. A comparison of eating patterns associated the Mediterranean diet with a 21% lower risk of heart disease versus a conventional low-fat diet (NaturalNews). Consistent with decades of evidence that fat quality and food quality beat fat-phobia. Observational comparison, so treat as confirmatory rather than novel.

THE THROUGH-LINE THIS WEEK

The lead is about timing. The Quick Hits are about inflammation, additives, minerals, immune signaling, and fat quality. Different topics — one underlying system.

Every item on this page is really about the metabolic and inflammatory environment your cells live in. Eating early improves insulin sensitivity and cools TNF-α. The longevity gene works by turning inflammation down. The preservative signal and the DASH and Mediterranean data are all about what that environment gets fed. Even the cancer breakthrough is an immune-signaling story — waking the body’s own defenses rather than poisoning everything.

Here’s the frame I keep coming back to: you don’t have a “weight problem” or a “blood pressure problem” or a “blood sugar problem” as separate silos. You have one metabolic-inflammatory terrain, and nearly every lever — when you eat, what you eat, how much low-grade inflammation you carry — pushes on the same underlying system. The eTRE finding is my favorite kind of result because it costs nothing: same food, earlier clock, measurably better metabolism. Start there this week. Pull dinner forward, kill the late-night snack, and let your circadian biology do the work.

GO DEEPER

If this resonated, there’s more where it came from. Subscribe to the newsletter at robertlufkinmd.substack.com to get the Brief in your inbox every week, and go deeper on the metabolic-root-cause framework on the Health Longevity Secrets podcast, where I unpack these threads with the scientists and clinicians doing the work.

Live well, longer, Robert Lufkin, MD

This newsletter is for educational purposes only and is not medical advice. It does not replace a personal relationship with a qualified health care professional. Talk with your own physician before changing your diet, exercise, medications, or supplements — especially if you have a medical condition or take prescription drugs.

THE LEAD: The GLP-1 Revolution Just Got Swallowable

For four years, the most powerful metabolic drugs of our lifetime have come with a catch: a needle. This week, that started to change. In the SOLSTICE trial, published in The Lancet, an oral small-molecule GLP-1 receptor agonist called elecoglipron delivered the kind of numbers we’ve come to expect from injectables — in pill form.

The phase 2b study randomized 406 adults with type 2 diabetes across nine countries to elecoglipron or placebo for 26 weeks (The Lancet, DOI 10.1016/S0140-6736(26)00802-0). At the top doses, up to 89.6% of participants hit an HbA1c of 7% or lower, versus 24.9% on placebo. Up to 72.3% lost at least 5% of body weight, compared with 20.2% on placebo. Tolerability looked like the rest of the GLP-1 class — the familiar GI story.

Here’s why I’m leading with this rather than the raw weight-loss figure. Injectable GLP-1s work spectacularly, but adherence in the real world is mediocre — a meaningful share of people stop within a year. A daily pill that reaches injectable-grade glycemic and weight outcomes could widen access dramatically, especially for the needle-averse and for the millions with insulin resistance who never progress to a prescription because the barrier feels too high.

Now the honest caveats. This is phase 2b, not phase 3 — 406 people, 26 weeks, funded by AstraZeneca, the drug’s maker. The reported 89.6% and 72.3% are maximum values across tested doses, not mean effects, and the paper doesn’t give absolute mean HbA1c or weight change. We don’t yet have head-to-head data against tirzepatide or oral semaglutide, and we don’t have long-term durability or cardiovascular outcomes. A pill is a delivery breakthrough, not a biology breakthrough — it still works by nudging the same incretin axis, and it doesn’t fix the upstream diet and lifestyle drivers of insulin resistance. But as a tool that could get effective therapy to far more people, this is a genuinely important step.

5 QUICK HITS

1. A longevity diet built on one amino acid dial. In Cell Metabolism, a low-protein, plant-forward Mediterranean-style diet supplemented with a precise amount of methionine extended healthspan, cut fat mass, and reduced frailty in older mice — while raising GLP-1, FGF21, and growth hormone (Cell Metabolism, DOI 10.1016/j.cmet.2026.05.015). Too little methionine caused frailty; too much abolished the benefit. A cross-sectional look at 200,000+ people pointed the same direction, with best outcomes on a largely plant-based pattern with fish added. Caveat: mouse healthspan (not lifespan) plus human epidemiology — a human trial is the next step.

2. Fish and a little meat beat “just eat less meat.” A 25-year Women’s Health Initiative analysis of 1,646 postmenopausal women found that a fish-and-moderate-meat pattern carried a 67% lower type 2 diabetes risk, while a high-dairy, high-solid-fat “lower-meat” pattern showed 2.6x higher cardiovascular risk than regular meat eaters (Gram Research summary). The lesson: cutting meat isn’t automatically protective — what replaces it decides the outcome. Observational, so confounding applies.

3. A metabolic “off-switch” behind cancer drug resistance. Researchers mapped a lipid-metabolism axis — SCD1–HDAC2–NPM1 — that helps breast and colorectal cancer cells survive treatment (MedComm, DOI 10.1002/mco2.70809). Blocking SCD1 re-sensitized the cells to HDAC inhibitors. It’s another data point that tumor metabolism — not just genetics — is a drug target. Caveat: cell lines and mouse models only, no human data yet.

4. Fish oil dampens insulin resistance in non-obese diabetes. In lean, diabetes-prone rats, omega-3 supplementation improved blood sugar, lipids, and inflammation — apparently by shifting immune cells toward an anti-inflammatory state (Nutrients, via ScienceDaily). It’s a reminder that insulin resistance isn’t only a “too much body fat” problem; inflammation is a lever too. Firmly preclinical — this is rats, not people.

5. Not all ultra-processed foods are created equal. A critical review of the NOVA classification argues the ultra-processed label lumps together genuinely harmful products and relatively benign ones, and that processing per se may matter less than what’s actually in the food (Proceedings of the Nutrition Society). A useful counterweight to headline panic — though the weight of evidence still links high UPF intake to worse cardiometabolic outcomes.

THE THROUGH-LINE THIS WEEK

Five different studies, one common thread: metabolism is the master switch.

The headline drug works by amplifying an incretin signal. The longevity diet works by tuning a single amino acid that moves GLP-1, FGF21, and growth hormone. The best anti-diabetes eating pattern is defined by what you put on the plate, not just what you take off. Even the cancer story is a metabolism story — tumors leaning on lipid pathways to dodge treatment. And the fish-oil data says insulin resistance is partly an inflammatory state, not purely a matter of body weight.

The temptation this week is to read “swallowable GLP-1” as we’ve solved it — just take the pill. I’d read it differently. A better delivery system for a good drug is real progress, and I’m glad more people will get access. But every other study on this page is pointing at the same upstream target the pill only touches downstream: the food, the amino acids, the inflammation, the metabolic environment your cells actually live in. The drug buys you leverage. The diet and lifestyle decide the terrain. Use the leverage — but don’t stop tending the terrain.

GO DEEPER

If this landed, the full conversation lives in two places. Subscribe to the newsletter at robertlufkinmd.substack.com so the Brief hits your inbox every week, and go deeper on the metabolic-root-cause framework on the Health Longevity Secrets podcast, where I take these threads apart with the researchers and clinicians doing the work.

Live well, longer,
Robert Lufkin, MD

This newsletter is for educational purposes only and is not medical advice. It does not replace a personal relationship with a qualified health care professional. Talk with your own physician before changing your diet, exercise, medications, or supplements — especially if you have a medical condition or take prescription drugs.

This week handed us the clearest real-world head-to-head yet between the two biggest metabolic drugs on the market — and, almost in the same breath, a string of studies showing that food, fasting, and daily behavior can move the same needles, sometimes further. The lesson isn’t “drugs bad, lifestyle good.” It’s that we finally have enough data to talk about both honestly, and to keep our eye on what actually sits upstream: metabolic health.

THE LEAD — Tirzepatide Beats Semaglutide Head-to-Head, But Read the Spread

For years the tirzepatide-versus-semaglutide debate ran on indirect comparisons. This week a large real-world analysis published in PNAS Nexus closed a lot of that gap: researchers matched roughly 10,300 patients on each drug from de-identified health records and followed them up to two years. Tirzepatide came out ahead — an average 14.7% weight loss versus 10.8% for semaglutide — and patients on tirzepatide were nearly twice as likely to be “high responders” (>15% body weight lost in year one: about 43% vs 22%). Counterintuitively, the tirzepatide group also reported fewer of the common GI side effects (Defiance Health summary of the PNAS Nexus study). This lines up with the head-to-head SURMOUNT-5 trial, so it’s not an outlier.

Here’s the contrarian beat: the average is the least interesting number in that study. Real-world outcomes ranged from minimal loss to more than 25% of body weight on the same drug. That enormous spread is the story. These molecules are extraordinary tools for the people who respond — but “the better drug” on a population chart is still an individual coin-flip in the clinic, and neither drug repairs the insulin resistance that put most of these patients on the path in the first place. They manage the fire; they don’t rebuild the wiring.

One honest caveat: this is a matched observational analysis of records, not a randomized trial. Matching reduces confounding but never eliminates it, and adherence in the real world differs from a trial protocol. Treat it as a strong, directionally clear data point — not a verdict.

1. A digital nutrition program put nearly 1 in 5 diabetics into remission — no drug required. A 12-month La Trobe University study of the “Defeat Diabetes” program found 78% of participants improved blood glucose, 42% pushed their HbA1c below the diabetes threshold, and 18% achieved remission with no glucose-lowering medication — while 13% came off their diabetes drugs entirely (La Trobe University, Diabetes Research and Clinical Practice). Metabolic read: type 2 diabetes is one of the few age-related diseases we can reverse — and you can deliver the intervention through a phone, not just a prescription pad.

2. The GrimAge clock beat every other aging clock — and crushed telomeres. NIA researchers compared the major epigenetic clocks for predicting mortality and found GrimAge outperformed PhenoAge, Horvath, Hannum, and DunedinPACE — and every clock beat telomere length, the old gold standard (Aging Cell, via NMN.com). Metabolic read: GrimAge is heavily weighted toward smoking and metabolic-stress signals, which is exactly why it tracks death so well — your DNA is keeping score of your daily inputs.

3. Ultra-processed food risk climbs with every single serving. In a large U.S. analysis presented at ACC.26, people eating about nine servings of ultra-processed food a day had a 67% higher risk of heart attack, stroke, or cardiac death versus those eating one — and each additional daily serving added more than 5% to the risk, even after adjusting for calories and overall diet quality (American College of Cardiology, via ScienceDaily). Metabolic read: there’s no safe “ignore it” threshold here — the dose-response runs all the way down, and the damage is largely a metabolic story.

4. A KRAS cancer vaccine plus checkpoint blockade showed early promise in one of the deadliest tumors. A phase I trial paired a mutant-KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer — a cancer notorious for resisting immunotherapy — and reported encouraging immune activation against the mutated KRAS protein (Wang et al., Nature Communications 2026, via Bioengineer.org). Metabolic read: teaching the immune system to see a cancer’s driver mutation is the right direction — early-phase and small, but a real step toward turning “undruggable” KRAS into a target.

5. Eating less just two days a week beat metformin for newly diagnosed diabetes. In a trial from the Chinese Academy of Medical Sciences, 5:2 intermittent fasting improved blood sugar control and produced more remissions than metformin or empagliflozin — with greater weight loss — after just 16 weeks (Chinese Academy of Medical Sciences, via NMN.com). Metabolic read: a behavioral pattern outperforming the single most-prescribed diabetes drug is not a fluke — it’s what happens when you treat the cause (chronic glucose/insulin load) instead of one downstream symptom.

THE THROUGH-LINE THIS WEEK

Look at the five findings together and one thesis keeps surfacing: insulin resistance and metabolic load sit upstream of nearly everything we’re trying to fix. The best GLP-1 drug manages weight brilliantly for responders but leaves the underlying metabolism untouched. Meanwhile a nutrition app, a 5:2 eating pattern, and cutting ultra-processed food each moved the same core metric — blood glucose and the metabolic dysfunction beneath it — sometimes outperforming pharmaceuticals head-to-head. Even the aging-clock story fits: GrimAge predicts death so well precisely because it reads the metabolic and lifestyle damage written into your DNA. And the cancer vaccine is a reminder that the immune system we’re trying to mobilize works better in a body that isn’t metabolically inflamed.

The honest synthesis isn’t anti-drug. Tirzepatide is a genuine advance. But if you only reach for the molecule and never address the daily inputs — what you eat, when you eat, how much processed food is in the cart — you’re managing the fire without ever fixing the wiring. The drugs buy time. The metabolism is what you’re actually trying to heal.

GO DEEPER

If this week’s through-line resonates, the deeper dives on metabolic health, GLP-1 drugs, and what actually reverses insulin resistance live on the Health Longevity Secrets podcast and in my long-form explainers — start there for the full picture behind these headlines.

If the Brief is useful to you, the best thing you can do is forward it to one person who’s weighing a GLP-1 decision or trying to get ahead of prediabetes — and if someone sent you here, subscribe so the next one lands in your inbox.

Live well, longer, Robert Lufkin, MD

This newsletter is for educational purposes only and is not medical advice. It does not establish a doctor-patient relationship. Always consult your own physician before making changes to your medications, diet, or health regimen.

Welcome back. This week handed us something rare in the longevity literature: not a mouse study, not a preclinical signal, but two decades of human data confirming what we keep coming back to here — the lever that moves the most disease is the one you control every day.

THE LEAD: A 20-year human trial just showed lifestyle beats the drug at preventing multiple chronic diseases

We talk a lot about single endpoints — lower this number, raise that one. But aging doesn’t arrive one disease at a time. It arrives as multimorbidity: two, three, four conditions stacking up at once. And this week a landmark analysis from the Diabetes Prevention Program and its long-term Outcomes Study (DPP/DPPOS), published in JAMA, put a hard number on how much we can bend that curve.

The setup: 1,173 adults with prediabetes, originally recruited in the late 1990s, randomized to one of three arms — an intensive lifestyle program, metformin, or placebo — and then followed for more than 20 years across 27 U.S. sites (University of Miami / InventUM).

The result: the lifestyle group had a 21% lower risk of developing multimorbidity — two or more chronic conditions — compared with placebo. The benefit held even when diabetes itself was removed from the equation, and it extended to lower rates of disease combinations involving stroke, chronic kidney disease, heart failure, and COPD (JAMA via InventUM).

The lifestyle “dose” was not exotic: reduced dietary fat, at least 150 minutes of weekly physical activity, and a 7% weight loss. That’s it.

Here’s the part worth sitting with. Metformin — the drug arm — did not produce a statistically significant reduction in multimorbidity (InventUM). I prescribe metformin and I think it has a real place. But this is a clean, head-to-head, two-decade reminder that a pharmacologic fix aimed at one pathway doesn’t replicate the system-wide effect of changing the inputs upstream.

One honest caveat: 85% of participants still developed at least two chronic conditions over follow-up (InventUM). Lifestyle doesn’t make you immortal. It compresses the morbidity — it pushes the disease curve to the right, which is exactly the goal.

1. The strength-training “sweet spot” for a longer life: 90–120 minutes a week. Tracking over 147,000 people for up to 30 years, researchers reporting in the British Journal of Sports Medicine found that 90–119 minutes of weekly resistance training was linked to a 13% lower all-cause mortality risk — plus a 19% lower risk of cardiovascular death and a 27% lower risk of neurological death. More than 120 minutes added nothing. Pairing it with aerobic work amplified the benefit. The metabolic read: muscle is an endocrine organ, and you don’t need to live in the gym to bank the returns.

2. A new GLP-1, survodutide, hit hard in fatty liver disease. The SYNCHRONIZE-1 trial, reported via the American College of Cardiology, showed the dual glucagon/GLP-1 agonist survodutide produced significant improvement in MASH (metabolic dysfunction-associated steatohepatitis) — the liver’s manifestation of insulin resistance. Promising, and worth watching, but this is a drug-trial endpoint on a disease that is fundamentally driven by diet and metabolic health.

3. Testosterone alone is not a metabolic shortcut. Presented at ENDO 2026, the T4DM trial of 1,007 men aged 50–74 found that testosterone improved body composition, glucose control, and libido — but only when paired with a lifestyle program, and most of the glucose benefit faded by year four (Endocrine Society). Lead author Gary Wittert put it plainly: testosterone “is not a replacement for lifestyle intervention, weight management or standard diabetes prevention.” A theme is forming this week.

4. Social inequality may literally speed up biological aging. A study from the Max Planck Institute for Human Development found that markers of social and economic disadvantage track with faster biological aging. It’s observational — we can’t infer causation — but it’s a reminder that the metabolic environment includes stress, access, and circumstance, not just plate and barbell.

5. Not all “five-a-day” portions are equal for your heart. Tracking more than 30,000 people across the UK and U.S. with actual biomarker measurements, researchers writing in Food & Function found that flavanol-rich choices — blueberries, blackberries, plums, cherries, broad beans, green tea — drove the cardiovascular benefit. Fewer than one in five people hit the ~500 mg/day flavanol threshold linked to lower heart-disease death, even among those eating five portions. What you count matters more than the count.

THE THROUGH-LINE THIS WEEK

Four of this week’s stories — the DPP lead, the T4DM testosterone trial, the survodutide liver data, and the flavanol study — circle the same truth from different angles: insulin resistance and the daily inputs that drive it sit upstream of almost everything we call “aging.”

The DPP trial is the cleanest statement of it I’ve seen in years. Twenty years out, a modest behavioral intervention beat a glucose-lowering drug at preventing the accumulation of chronic disease — not because metformin is useless, but because multimorbidity is a metabolic-systems problem, and you treat systems by changing inputs, not by patching a single output. The testosterone data say the same thing in a different vocabulary: the hormone helps, but only as an amplifier of lifestyle, never a substitute. Even the strength-training “sweet spot” fits — resistance training is, at its core, an insulin-sensitizing intervention with a remarkably low effective dose.

The practical takeaway isn’t new, but the evidence keeps getting stronger: protect your insulin sensitivity. Lift twice a week. Eat the flavanol-dense plants, not just any plants. Move 150 minutes a week. None of it is glamorous. All of it compounds.

GO DEEPER

If this lens is useful to you, the long-form work lives in two places. The Health Longevity Brief lands here every Thursday with the week’s signal pulled from the noise. And on the Health Longevity Secrets podcast — and in my explainer videos — I sit down with the researchers and clinicians doing this work and go deep on the mechanisms behind the headlines.

Subscribe, forward this to one person who needs it, and reply with what you’d like me to dig into next. Your questions shape what I cover.

Live well, longer,
Robert Lufkin, MD

This newsletter is for educational purposes only and is not medical advice. It does not establish a doctor-patient relationship. Always consult your own physician before making changes to your medications, diet, exercise, or health regimen.